Latest period
$7.67B
YoY change
+3.9%
5Y CAGR
-6.4%
Peak year (2010)
$12.55B
Latest annual
$5.74B
Cash on Hand history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $5.74B
Cash on Hand growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +3.9%
Cash on Hand history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $5.74B | +3.9% | +$216.00M | ||
| 2024 | $5.53B | -5.7% | −$335.00M | ||
| 2023 | $5.86B | -6.1% | −$383.00M | ||
| 2022 | $6.24B | -2.4% | −$155.00M | ||
| 2021 | $6.40B | -19.9% | −$1.59B | ||
| 2020 | $7.99B | +28.6% | +$1.77B | ||
| 2019 | $6.22B | +9.5% | +$537.00M | ||
| 2018 | $5.68B | +24.7% | +$1.13B | ||
| 2017 | $4.55B | -22.8% | −$1.35B | ||
| 2016 | $5.90B | -13.9% | −$951.00M | ||
| 2015 | $6.85B | -4.2% | −$302.00M | ||
| 2014 | $7.16B | -28.5% | −$2.86B | ||
| 2013 | $10.01B | +17.5% | +$1.49B | ||
| 2012 | $8.52B | -27.9% | −$3.29B | ||
| 2011 | $11.82B | -5.8% | −$731.00M | ||
| 2010 | $12.55B | +9.8% | +$1.12B | ||
| 2009 | $11.43B | +160.2% | +$7.04B | ||
| 2008 | $4.39B | -27.3% | −$1.65B | ||
| 2007 | $6.04B | -22.1% | −$1.72B | ||
| 2006 | $7.76B | +17.5% | +$1.16B | ||
| 2005 | $6.60B | +25.4% | +$1.34B | ||
| 2004 | $5.26B | +33.3% | +$1.31B | ||
| 2003 | $3.95B | -15.7% | −$737.00M | ||
| 2002 | $4.69B | -14.2% | −$776.88M | ||
| 2001 | $5.46B | +22.7% | +$1.01B | ||
| 2000 | $4.45B | +35.5% | +$1.17B | ||
| 1999 | $3.29B | +433.7% | +$2.67B | ||
| 1998 | $615.82M | -48.9% | −$589.30M | ||
| 1997 | $1.21B | -27.8% | −$464.57M | ||
| 1996 | $1.67B | +36.4% | +$445.88M | ||
| 1995 | $1.22B | +6.5% | +$74.71M | ||
| 1994 | $1.15B | -25.9% | −$402.58M | ||
| 1993 | $1.55B | +144.8% | +$917.71M | ||
| 1992 | $633.98M | -2.9% | −$19.07M | ||
| 1991 | $653.04M | +6.5% | +$39.64M | ||
| 1990 | $613.40M | — | — |
- 2025$5.74B+3.9%
- 2024$5.53B-5.7%
- 2023$5.86B-6.1%
- 2022$6.24B-2.4%
- 2021$6.40B-19.9%
- 2020$7.99B+28.6%
- 2019$6.22B+9.5%
- 2018$5.68B+24.7%
- 2017$4.55B-22.8%
- 2016$5.90B-13.9%
- 2015$6.85B-4.2%
- 2014$7.16B-28.5%
- 2013$10.01B+17.5%
- 2012$8.52B-27.9%
- 2011$11.82B-5.8%
- 2010$12.55B+9.8%
- 2009$11.43B+160.2%
- 2008$4.39B-27.3%
- 2007$6.04B-22.1%
- 2006$7.76B+17.5%
- 2005$6.60B+25.4%
- 2004$5.26B+33.3%
- 2003$3.95B-15.7%
- 2002$4.69B-14.2%
- 2001$5.46B+22.7%
- 2000$4.45B+35.5%
- 1999$3.29B+433.7%
- 1998$615.82M-48.9%
- 1997$1.21B-27.8%
- 1996$1.67B+36.4%
- 1995$1.22B+6.5%
- 1994$1.15B-25.9%
- 1993$1.55B+144.8%
- 1992$633.98M-2.9%
- 1991$653.04M+6.5%
- 1990$613.40M—
Cash on Hand values are taken from AstraZeneca's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's latest reported cash and short-term investments is $7.67B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, AstraZeneca (AZN) reported cash and short-term investments of $5.74B – edged up 3.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca cash and short-term investments compounded at -6.4% per year, with a net decline across the window.
AstraZeneca cash and short-term investments peaked at $12.55B in 2010; the latest annual figure is $5.74B in 2025 (54.3% below peak).
Across the available history, cash and short-term investments reached its high of $12.55B in 2010 and its low of $613.40M in 1990.
AstraZeneca Cash on Hand by Year
AstraZeneca Cash on Hand 2025: $5.74B
In 2025, AstraZeneca reported cash and short-term investments of $5.74B, edged up 3.9% from 2024.
AstraZeneca Cash on Hand 2024: $5.53B
AstraZeneca cash and short-term investments in 2024 was $5.53B, declined 5.7% below 2023.
AstraZeneca Cash on Hand 2023: $5.86B
2023's cash and short-term investments for AstraZeneca came in at $5.86B, declined 6.1% below 2022.
AstraZeneca Cash on Hand 2022: $6.24B
AstraZeneca posted cash and short-term investments of $6.24B in 2022, edged down 2.4% below 2021.
AstraZeneca Cash on Hand 2021: $6.40B
AstraZeneca cash and short-term investments in 2021 was $6.40B.
See more financial history for AstraZeneca (AZN).
Sector peers by Cash on Hand
Healthcare peers of AstraZeneca (AZN), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $10.11B | |
| $9.13B | |
| $7.27B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.26B
- $4.24B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation